Quest Diagnostics (NYSE:DGX) Price Target Raised to $250.00

Quest Diagnostics (NYSE:DGX) had its price target boosted by Truist Financial from $225.00 to $250.00 in a report published on Friday,Benzinga reports. They currently have a hold rating on the medical research company’s stock.

A number of other research analysts have also recently issued reports on DGX. Robert W. Baird lifted their price target on shares of Quest Diagnostics from $236.00 to $255.00 and gave the company a “neutral” rating in a research report on Friday. Barclays upped their price objective on shares of Quest Diagnostics from $230.00 to $250.00 and gave the stock an “overweight” rating in a report on Thursday. UBS Group reaffirmed a “neutral” rating and set a $232.00 target price on shares of Quest Diagnostics in a research note on Friday. Jefferies Financial Group reiterated a “buy” rating and set a $245.00 target price on shares of Quest Diagnostics in a report on Thursday. Finally, Evercore set a $225.00 price target on Quest Diagnostics in a research report on Tuesday, April 21st. Six equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, Quest Diagnostics presently has an average rating of “Moderate Buy” and a consensus target price of $231.73.

Quest Diagnostics Price Performance

Shares of DGX stock opened at $228.05 on Friday. The business’s fifty day moving average is $203.23 and its 200 day moving average is $197.76. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.72. The stock has a market cap of $25.17 billion, a price-to-earnings ratio of 24.21, a PEG ratio of 2.61 and a beta of 0.58. Quest Diagnostics has a twelve month low of $165.78 and a twelve month high of $237.78.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $3.12 EPS for the quarter, beating the consensus estimate of $2.82 by $0.30. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.The business had revenue of $3.04 billion during the quarter, compared to analyst estimates of $2.97 billion. During the same quarter last year, the firm posted $2.62 earnings per share. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. Research analysts expect that Quest Diagnostics will post 11.17 EPS for the current fiscal year.

Quest Diagnostics Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, July 22nd. Investors of record on Wednesday, July 8th were paid a $0.86 dividend. The ex-dividend date was Wednesday, July 8th. This represents a $3.44 dividend on an annualized basis and a yield of 1.5%. Quest Diagnostics’s payout ratio is presently 36.52%.

Insider Activity

In other news, CEO J. E. Davis sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $194.14, for a total value of $1,941,400.00. Following the transaction, the chief executive officer owned 132,423 shares in the company, valued at approximately $25,708,601.22. This represents a 7.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karthik Kuppusamy sold 8,147 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $200.00, for a total transaction of $1,629,400.00. Following the sale, the senior vice president owned 13,510 shares in the company, valued at approximately $2,702,000. The trade was a 37.62% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.88% of the company’s stock.

Hedge Funds Weigh In On Quest Diagnostics

A number of hedge funds have recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. boosted its position in shares of Quest Diagnostics by 346.5% during the fourth quarter. Assenagon Asset Management S.A. now owns 24,949 shares of the medical research company’s stock valued at $4,329,000 after buying an additional 19,361 shares during the last quarter. Davis Selected Advisers increased its holdings in Quest Diagnostics by 16.8% in the 4th quarter. Davis Selected Advisers now owns 1,589,883 shares of the medical research company’s stock worth $275,895,000 after buying an additional 228,271 shares in the last quarter. Capital Management Associates Inc purchased a new position in Quest Diagnostics in the 4th quarter worth about $1,024,000. ANTIPODES PARTNERS Ltd raised its position in Quest Diagnostics by 178.7% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 171,987 shares of the medical research company’s stock worth $29,847,000 after buying an additional 110,280 shares during the last quarter. Finally, Advisors Capital Management LLC lifted its stake in Quest Diagnostics by 5.4% during the 4th quarter. Advisors Capital Management LLC now owns 313,838 shares of the medical research company’s stock valued at $54,460,000 after acquiring an additional 16,194 shares during the period. 88.06% of the stock is currently owned by hedge funds and other institutional investors.

Key Quest Diagnostics News

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Quest Diagnostics posted Q2 results that beat Wall Street expectations on both revenue and earnings, helped by stronger demand for routine diagnostic and preventive testing. The company also raised its full-year 2026 outlook, which investors are reading as evidence that growth is holding up well. Article: Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
• Positive Sentiment: Mizuho raised its price target on DGX to $260 and kept an outperform rating, signaling confidence that the company can still outperform from here. Article: Quest Diagnostics price target raised by Mizuho
• Positive Sentiment: Truist also lifted its target to $250, while Robert W. Baird increased its target to $255, reflecting continued analyst optimism after the earnings beat and raised guidance. Article: Quest Diagnostics price target raised by Truist Financial Corporation
• Neutral Sentiment: Several market commentary pieces highlighted DGX as a momentum stock and noted the shares recently reached a 52-week high. That supports bullish sentiment, but these articles are mostly follow-up coverage rather than a new fundamental catalyst. Article: Are You Looking for a Top Momentum Pick? Why Quest Diagnostics (DGX) Is a Great Choice

About Quest Diagnostics

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.